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Abstract
Background: Our previous study showed that GATA6 plays important roles in cholangiocarcinoma (CCA) cell
invasion and metastasis. However, the regulation mechanism of GATA6 in CCA is not clear. In this study, we studied
the potential function of miR-124 in CCA and the mechanism of GATA6 regulation.
Methods: The expression levels of miR-124 and GATA6 in cancerous tissues from 57 CCA patients was detected by
RT-PCR and IHC. The impact of miR-124 on GATA6 expression in CCA cells was evaluated using cell transfection,
xenotransplantation into nude mice and a luciferase reporter assay.
Results: miR-124 was decreased in 57 cancerous tissue samples compared with 38 matched paracancerous
samples. The miR-124 level was inversely associated with lymph node involvement and distant metastasis. miR-124
significantly inhibited invasion and migration of CCA cells in vitro. Furthermore, miR-124 inhibited CCA cell
metastasis in nude mice. miR-124 inhibited the luciferase activity of reporter genes containing the wild-type GATA6
3′-UTR, which was abrogated by mutation of the binding site. The protein levels of GATA6 were negatively
regulated by miR-124. miR-124 expression was inversely associated with GATA6 in 57 cancerous samples. The
miR-124-induced suppression of CCA invasion was abrogated by remedial expression of GATA6. GATA6 expression
was decreased by miR-124 overexpression in liver masses from nude mice.
Conclusions: Our data suggested that miR-124 decreases GATA6 expression by targeting its 3′-UTR, which in turn
inhibits CCA invasion and metastasis.
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Background
Cholangiocarcinoma (CCA) is a highly malignant cancer
with a poor prognosis. Radical resection provides the
only option for cure. However, only a small proportion
of CCA patients can receive surgery because of the
metastatic nature of the disease [1]. Metastasis is a mul-
tistep process by which primary tumour cells invade
adjacent tissues, enter the bloodstream, survive in circu-
lation, extravasate into the surrounding tissue paren-
chyma, and finally form clinically detectable metastases
[2]. This multistep process is initiated and regulated
through the alteration of numerous molecules acting as
oncogenes or suppressors. Thus far, a number of altered
molecules and the related signalling pathways have been
reported [3, 4]. However, the invasion and metastasis of
CCA might be regulated by a molecular network that is
far from completely understood.
Among the molecules that are altered during CCA
progression, our previous study found that GATA6, a
member of an evolutionarily conserved family of zinc
finger transcription factors, is aberrantly upregulated [5].
In addition, GATA6 promoted CCA invasion and metas-
tasis. These results indicate that GATA6 acts as a poten-
tial oncogene in CCA. While the mechanism of GATA6
upregulation in CCA is unclear, the upregulation might
be attributed to amplification of promoting factors and
inhibition of blocking factors. Kwei et al. [6] reported
that amplification of the GATA6 gene might contribute
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to the aberrant expression of GATA6, which is one amp-
lification promoting factor. However, there are few
reports that mention the inhibition of blocking factors
of GATA6 in CCA.
MicroRNAs (miRs) are small noncoding RNA oligonu-
cleotides that regulate a large number of genes. They per-
form the negative regulation through complementary
binding to mRNAs 3′-untranslated regions (UTRs). A
growing body of evidence suggests that some miRNAs
function as onco-miRs or tumour-suppressor miRs by
targeting known oncogenes or tumour-suppressor genes
[7–10]. Thus, we hypothesized that miRs might participate
in negative regulation of GATA6 in CCA. Among the
numerous miRNAs, we focused on miR-124 based on the
following observations: (1) Recently, mir-124 was reported
to be downregulated and to affect metastasis in several
types of cancer, including hepatocellular carcinoma, pancre-
atic cancer, breast cancer, prostate cancer, glioma and lung
cancer [11–16]. However, its role in CCA is uncertain. (2)
Bioinformatics analysis has shown that the 3′-UTR of
GATA6 gene contains a potential miR-124 binding site. (3)
Our preliminary experiments indicated that the level of
miR-124 is negatively associated with GATA6 in a CCA cell
line, QBC939. Thus, we postulate that miR-124 might par-
ticipate in the regulation of GATA6 in CCA.
In the present study, the expression profile of miR-124
in CCA samples was investigated. The role of miR-124
on CCA cell migration, invasion and metastasis was also
investigated. Finally, we examined the mechanism of
miR-124 in regulating GATA6 in CCA cells. Based on
the present study, we may abandon the mechanism of
CCA metastasis. In addition, miR-124 may potentially be




In total, 57 frozen cancerous samples from CCA patients
undergoing surgery from 2005 to 2010 at our depart-
ment were collected in this study. In addition, 38
matched paracancerous samples were collected. The
clinical features were obtained.
Overall survival was defined from surgery date to until
the date of last contact. Recurrence-free survival was cal-
culated from the date of surgery until the date of tumour
recurrence.
Cell culture
QBC939 and RBE, two human cholangiocarcinoma cell
lines, were cultured in RPMI 1640 medium with 10%
foetal bovine serum (HyClone). Primary biliary epithelial
cells were bought from ScienCell Research Laboratories
(San Diego, CA, USA) and cultured using the media
comprising DMEM/F12 (1:1) with 10% foetal bovine
serum (FBS), 25 ng/mL epidermal growth factor and
393 ng/mL dexamethasone.
Cell transfection
GATA6 transfection was performed as previously
described [5]. In brief, The CDS template of GATA6
without the miR-124 binding site was synthesized chem-
ically and amplified by PCR. Then, DNA was validated
by sequencing and cloned into a pCMX plasmid. A total
of 10 μg of GATA6 plasmid (ExGATA6) or empty
plasmid (ExControl) were transfected into cells using
Lipofectamine LTX and Plus Reagent (Invitrogen, USA).
Cells were transfected with 100 nM miR-124 mimic
(ExmiR-124) or 200 nM miR-124 inhibitor (InmiR-124)
(Ribobio, Guangzhou, China) in the six-well plate using
Lipofectamine 2000 (Invitrogen). After 24 and 48 h, the
expression was evaluated by real-time PCR.
Xenotransplantation of CCA cells into nude mice
CCA cell metastasis was evaluated following xenotrans-
plantation into nude mice by intrasplenic injection as pre-
vious described [5]. In brief, Cells (5 × 105) were injected
into the spleen of 4-week-old male nude mice (Laboratory
Animal Centre, Third Military Medical University). The
mice were sacrificed after 1 month. Tumour masses were
primarily found in the spleen, liver and bowel grossly at
autopsy. All masses except those in the spleen were con-
sidered distant metastases. Distant masses were embedded
in paraffin, stained with haematoxylin and eosin (HE), and
examined under a microscope.
QBC939 cells were transfected with a miR-124 agomir
(200 nM) or an negative control for 48 h (200 nM)
(Ribobio, Guangzhou, China). Intraperitoneal injection
was performed with miR-124 agomir (5 nmol each) or
negative control agomir (5 nmol each) twice a week for
2 weeks, which began at week 3 after xenotransplantation.
Luciferase reporter assays
CCA cells (5 × 104) were seeded in a 48-well plate. The
cells were co-transfected with 10 nM miR-124 mimics
or NC and 10 ng of firefly luciferase reporter construct.
The reporter contained either a wild-type or mutant
GATA6 3′-UTR. Luciferase activities were analysed 48 h
after transfection using a Dual-Luciferase Reporter Assay
System (Promega) in an M200 microplate fluorescence
reader (Tecan, Vienna, Austria).
Cell invasion (Transwell) or migration (wound healing)
assay
Cell invasion (Transwell) assay was performed as previ-
ously described [5]. Briefly, 2 × 105 cells were suspended
in 400 μL of serum-free RPMI 1640 medium and seeded
in the top chamber that had been coated with a layer of
extracellular matrix (BD Biosciences, USA). Complete
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medium with serum (500 μl) was added to the bottom
chamber. After 48 h of incubation, the cells that had in-
vaded through the extracellular matrix layer to the lower
surface of the filters were stained. Photographs of three
randomly selected fields of the fixed cells were captured,
and cells were counted. Experiments were repeated inde-
pendently three times.
Cells were seeded in a 6-well plate, grown until conflu-
ence, and then starved for 24 h. A linear wound was
made by scraping a pipette tip through the confluent
cells. The cell motility was measured in terms of wound
closure by photographing three random fields 72 h after
the wound was made. Experiments were repeated inde-
pendently three times.
Real-time PCR
Total RNA extraction was performed using TRIzol re-
agent (Invitrogen, Grand Island, NY, USA) according to
the manufacturer’s instructions. The RNAs were mixed
with oligo (dT) or miRNA-specific stem-loop RT
primers and reverse transcribed to cDNA using M-MLV
Reverse Transcriptase (Promega, Madison, WI, USA).
These cDNAs were used to analyse the expression of
miR-124 and GATA6 by qPCR using a SYBR premix Ex
Taq kit (TaKaRa, Dalian, China). The expression levels
were normalized against endogenous β-actin or U6
mRNA as controls. All reactions were performed in an
ABI 7500 system (Applied Biosystems, Foster, CA, USA)
in triplicate, and the levels of gene expression were cal-
culated using the 2-ΔΔCT method. All primers are shown
in Additional file 1: Table S1.
Western blot analysis
Western blot analysis was performed as previously de-
scribed [5]. The total protein in CCA cells was isolated
using RIPA Lysis Buffer (Beyotime, China). For immuno-
blotting, equal amounts of proteins were separated on a
5–8% SDS-PAGE gel and electrophoretically transferred
onto nitrocellulose membranes (Millipore), which were
blocked in TBST containing 5% milk for 2 h at RT and
blotted with antibody overnight at 4 °C using anti-
GATA6 (1:500, Abcam) or β-actin (1:500, Biotechnology).
After washing membranes with TBST and incubating
them with either anti-rabbit or anti-mouse horseradish
peroxidase-conjugated secondary antibody (Biosynthesis
Biotechnology, China) for 2 h at room temperature,
immunocomplexes were visualized using chemilumines-
cence (GE, USA) following the manufacturer’s protocol.
Statistical analysis
Data were analysed using SPSS 17.0 software. Continu-
ous data were measured with a t-test. For categorical
data, chi-square analysis or Fisher’s exact test was used.
Kaplan-Meier analysis was applied for overall survival
and recurrence-free survival. Statistical significance was
set at P < 0.05.
Results
Decreased expression of miR-124 is correlated with
higher metastatic behaviour in clinical CCAs
We first compared the miR-124 expression in 57 CCA
tissue samples and 38 matched paracancerous samples.
The primers used for real time-PCR are in Additional
file 1: Table S1. The miR-124 level was significantly
lower in cancerous samples compared with paracancer-
ous samples (Fig. 1a), indicating that expression of miR-
124 decreased in CCA. Among the 57 cancerous
samples, 25 samples with lymph node involvement
showed a lower miR-124 level compared with 32
samples without lymph node involvement (Fig. 1b).
Moreover, 17 cancerous samples with distant metastasis
exhibited a lower miR-124 level compared with 40
samples without distant metastasis (Fig. 1c). miR-124 ex-
pression was separated to high and low levels according
to the median value. A low miR-124 level significantly
related with lymph node involvement but not with gen-
der, age, location, histological grade, or T status (Table 1).
The data suggested that miR-124 expression is decreased
in CCA, and decreased miR-124 level is correlated with
enhanced metastatic behaviour.
miR-124 inhibits CCA cell invasion and metastasis in vitro
and in vivo
Because the clinical data indicated an negative correl-
ation between miR-124 and metastatic behaviour, we
next investigated the effect of miR-124 on migration and
invasion in QBC939 and RBE CCA cell lines. Real-time
PCR showed the miR-124 levels were decreased in both
QBC939 and RBE cells compared with primary biliary
epithelial cells (Fig. 2a). Because QBC939 cells exhibited
a lower miR-124 level, overexpression of miR-124 was
induced in QBC939 cells (Fig. 2b), and downregulation
of miR-124 was performed in RBE cells (Fig. 2c). Trans-
well assays showed a significant decrease in QBC939 cell
invasion after miR-124 overexpression (Fig 2d), whereas
RBE cell invasion was significantly increased by miR-124
downregulation (Fig. 2d). Moreover, cell migration was
significantly decreased by miR-124 overexpression in
QBC939 cells and upregulated by miR-124 inhibition in
RBE cells (Fig. 2e). These data suggested that miR-124
inhibited CCA migration and invasion in vitro. Next, we
investigated the role of miR-124 on CCA cell metastasis.
QBC939 cells were injected into the spleens of nude
mice. Distant masses were detected at autopsy and by
HE staining. The number of distant masses was signifi-
cantly lower by miR-124 overexpression (Fig. 2f ). These
data suggested that miR-124 inhibits invasion and
metastasis of CCA cells.
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miR-124 downregulates GATA6 expression by directly
targeting its 3′-UTR
We then investigated the role of miR-124 on GATA6 ex-
pression in CCA cells. Western blot analysis showed that
GATA6 protein levels were downregulated by miR-124
overexpression in QBC939 cells (Fig. 3a) and upregu-
lated by miR-124 inhibition in RBE cells (Fig. 3b). The
correlation between miR-124 and GATA6 was also eval-
uated in the 57 clinical CCA samples. GATA6 protein
expression was observed using immunohistochemistry
(IHC). A total of 27 samples (47%) showed GATA6-
positive staining (Fig. 3c). miR-124 levels was negatively
correlated with GATA6 in 57 CCA samples (Fig. 3d).
The above data indicated that GATA6 might be regu-
lated by miR-124 in CCA cells. miRNAs perform post-
transcriptional regulation through binding to the mRNA
3′-UTR. Because a bioinformatics prediction analysis in-
dicated that the 3′-UTR of GATA6 mRNA had a target
site for miR-124, we determined whether miR-124
downregulated GATA6 by targeting its 3′-UTR. The lu-
ciferase reporters were constructed containing mutant
or wild-type 3′-UTRs of the GATA6 gene (Fig. 3e) and
cotransfected them with miR-124 mimics into QBC939
cells. miR-124 significantly inhibited the luciferase activ-
ity of reporter genes containing the wild-type GATA6
3′-UTR, whereas the inhibition was significantly rescued
by mutating the miR-124-binding site (Fig. 3f ). Taken to-
gether, our data indicate that miR-124 downregulates
GATA6 expression by directly targeting its 3′-UTR.
miR-124 inhibits CCA invasion and metastasis by
downregulating GATA6
To investigate whether miR-124 inhibited CCA invasion
and metastasis through targeting GATA6, plasmids
carrying the entire coding sequence of GATA6 without
the miR-124 binding sites were transfected into QBC939
cells to rescue miR-124 -induced downregulation of
GATA6 (Fig. 4a and b). Remedial GATA6 expression
significantly abrogated the miR-124-induced suppression
of QBC939 cell invasion and migration in Transwell and
wound healing assays (Fig. 4c and d). In addition, we
detected GATA6 expression in liver masses from the
xenotransplanted mice using IHC. GATA6 was de-
creased in the miR-124 group (Fig. 4e), which was
consistent with the diminished metastatic behaviour. We
Fig. 1 miR-124 expression is correlated with enhanced metastatic behaviour in 57 CCA clinical samples. a miR-124 levels between CCA cancerous
samples (N = 57) and paracancerous samples (N = 38). b miR-124 levels between CCA primary cancerous samples with lymphnode involvement
(N = 32) and without lymphnode involvement (N = 25). c miR-124 levels between CCA primary cancerous samples with distant metastasis (N = 17)
and without distant metastasis (N = 40). *P <0.05
Table 1 Clinical features of the CCA patients (n = 57) according
to miR-124 expression grouping
Features MiR-124 Expression P valueb
High (N = 29) Low (N = 28)
Age 55.9 ± 9.7 56.0 ± 10.8 0.969
Gender 0.516
Male 18 (62%) 15 (54%)
Female 11 (38%) 13 (46%)
Location 0.682
Intrahepatic 4 (14%) 6 (21%)
Extrahepatic 25 (86%) 22 (79%)
Histological Grade 0.580
G1 6 (21%) 4 (14%)
G2 21 (72%) 20 (71%)
G3 2 (7%) 4 (14%)
T classificationa 0.741
T1 7 (10%) 4 (33%)
T2 9 (44%) 8 (27%)
T3 8 (28%) 9 (25%)
T4 5 (18%) 7 (15%)
Lymphnode involvement 0.012c
Yes 8 (28%) 17 (61%)
No 21 (72%) 11 (39%)
Distant metastasis 0.125
Yes 6 (21%) 11 (39%)
No 23 (79%) 17 (61%)
The median value was defined as the cut-off point separating high and low
expression of miR-124
aAccording to the 6th UICC-TNM staging
bP value is for t test (continuous variables) or chi-square or Fisher’s exact test
(catigorical variables)
CP < 0.05, statistical significance
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also determined the miR-124 expression level in the liver
masses and found that miR-124 was increased in the
miR-124 group (Fig. 4f ). Our data suggest that miR-124
might inhibit invasion and metastasis of CCA cells
through downregulation of GATA6.
miR-124 expression is negatively correlated with
prognosis in CCA patients
Because recurrence and metastasis are major factors for
a poor prognosis, we next investigated the relation be-
tween the expression of miR-124 and prognosis in 57
Fig. 2 miR-124 inhibits CCA cell invasion and metastasis. a The miR-124 levels in two CCA cell lines, QBC939 and RBE, were lower than those in
cultured primary biliary epithelial cells, determined by real-time PCR analysis. b, c Validation of the miR-124 levels after transfection. d The effect
of miR-124 overexpression on CCA cell invasion, as shown by Transwell assays in vitro. e The effect of miR-124 overexpression on CCA
cell migration according to wound healing assays in vitro. f The effect of miR-124 overexpression on QBC939 cell metastasis following
xenotransplantation into nude mice by intrasplenic injection. In-miR-124: CCA cells transfected with miR-124 inhibitors; Ex-miR-124: CCA
cells transfected with miR-124 mimics. *P < 0.05
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CCA patients. miR-124 expression were separated to
high and low levels by the median value. We compared
postoperative and disease-free survival between miR-
124high and miR-124low patients with a Kaplan-Meier
analysis. MiR-124low patients had significantly poorer
overall survival (Fig. 5a) and a higher rate of recurrence
(Fig. 5b). Therefore, the result suggest that miR-124
expression is negatively correlated with the prognosis of
CCA patients.
Discussion
Deregulation of miRs has been reported in various cancer
tissues from numerous profiling data [17]. Moreover, these
small non-coding RNAs can function as oncogenes or
tumour-suppressor genes that contribute to tumourigenesis
and progression [8]. In the present study, we found miR-124
was downregulated in cancerous samples from CCA pa-
tients. Downregulation of miR-124 contributed to CCA in-
vasion and metastasis, indicating its tumour-suppressor
function. In addition, we demonstrated that GATA6 is a
new potential target of miR-124. miR-124 downregulated
GATA6 by targeting the 3′-UTR. Moreover, miR-124 inhib-
ited CCA cell invasion and metastasis by downregulating
GATA6. Taken together, these findings suggest an important
role of miR-124 in CCA invasive and metastatic potential.
miR-124 has been reported to be downregulated by the
hepatitis C virus (HCV) core protein in HCV-related intra-
hepatic CCA [18]. Here, we found that miR-124 was down-
regulated in both intrahepatic and extrahepatic CCA.
Furthermore, many miR-124-decreased CCA patients did
not have HCV infections, indicating that there might be
other mechanisms regulating miR-124 expression during
CCA progression. Recent studies have shown that aberrant
DNA methylation plays important roles in miR-124 down-
regulation in several types of cancers, including hepatocel-
lular carcinoma, gastric cancer, colon cancer, lung cancer,
lymphoma, and pancreatic cancer [12, 19–21]. Whether
DNA methylation also participates in the downregulation
of miR-124 in CCA, especially HCV-negative CCA, needs
to be investigated further.
Fig. 3 miR-124 downregulates GATA6 expression by directly targeting its 3′-UTR in CCA cells. a, b The effect of miR-124 overexpression and
downregulation on GATA6 protein levels in CCA cells, determined by western blot analysis. c, d Correlation between GATA6 and miR-124
expression in 57 CCA samples. e Mutation of the potential binding site in the 3′-UTR of GATA6. f The effect of miR-124 on the relative luciferase
activity of the GATA6 wild-type and mutant 3′-UTR constructs. In-miR-124: CCA cells transfected with miR-124 inhibitors; Ex-miR-124: CCA cells
transfected with miR-124 mimics. *P < 0.05, **P < 0.01
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Dysregulation of GATA6 has been reported in several
types of cancers. It functions as a promoter and suppres-
sor according to the tumour origin. Our previous study
showed that GATA6 is aberrantly upregulated in CCA,
which indicates that it functions as a potential oncogene
[5]. Kwei et al. [6] reported that an increased gene copy
number contributes to the aberrant expression of
GATA6. Wang et al. [22] reported that DeltaNp63alpha,
the oncogenic isoform of the p63 protein, regulates
GATA6 expression in gastric cancer. Here, we showed
that a downregulation of miR-124 expression might con-
tribute to the aberrant expression of GATA6 in CCA.
Both of the above studies suggest that the dysregulation
of GATA6 expression during CCA progression is
controlled by multiple pathways, including the enhance-
ment of positive regulation pathways and the inhibition
of negative regulation pathways.
GATA6 participates in cancer progression by regulating
certain key molecules. Among these key molecules, 67LR
is an important protein that is regulated by GATA6
through binding to its prompter region in CCA [5]. 67LR
is a cell surface non-integrin receptor expressed in epithe-
lial cells that mediates cell attachment to laminin. An in-
crease in 67LR expression has been found in a variety of
cancers including CCA [23, 24]. 67LR promotes CCA cell
invasion and metastasis through various mechanisms, in-
cluding facilitating tumour cell invasion into adjacent
tissue by upregulating proteolytic enzymes [25, 26] and
Fig. 4 miR-124 inhibits CCA cell invasion and metastasis by downregulating GATA6. a, b Validation of miR-124 and GATA6 levels after transfection.
c, d Remedial expression of GATA6 significantly abrogated the miR-124-induced suppression of QBC939 cell invasion and migration in Transwell
and wound healing assays. e IHC analysis of GATA6 expression in the liver masses of xenotransplanted mice. f Validation of miR-124 expression in
the liver masses. Ex-miR-124: CCA cells transfected with miR-124 mimics. *P < 0.05
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assisting tumour cell survival in the circulatory system by
promoting immune privilege [27]. By targeting GATA6,
miR-124 may also downregulate 67LR expression and play
important roles in these processes during CCA cell metas-
tasis. The present results, together with the above
evidence, indicate the important role of the miR-124-
GATA6-67LR pathway in CCA cell invasion and
metastasis.
Although our results showed a potential new target of
miR-124 and the important role of this pathway in CCA
cell metastasis, there must be other pathways by which
miR-124 exerts its effects. Previous studies have shown
that miR-124 inhibits cancer cell invasion and metastasis
by targeting other molecules, including slug [13], Rac-1
[12, 28], SMYD3 [18], SphK1 [29], and ROCK1 [30].
GATA6 is also reported to participate in cancer cell inva-
sion and metastasis by regulating other proteins, such as
urokinase plasminogen activator [31], slug [32] and BMP4
[33]. All of this evidence suggests that invasion and metas-
tasis of cancers including CCA is regulated by a molecular
network. Our previous and present results suggest that
miR-124 and GATA6 play important roles in this network.
In addition to metastasis, GATA6 is reported to play
important roles in tumourigenesis, self-renewal of cancer
stem cells, and proliferation and apoptosis of various
types of cancer [22, 33–35]. miR-124 is also reported to
participate in regulating angiogenesis, chemosensitivity
and proliferation of cancers [14, 36, 37]. Whether miR-
124 participates in regulating other hallmarks of CCA by
targeting GATA6 needs to be investigated further.
Conclusion
In conclusion, we show miR-124 is downregulated in
CCA. miR-124 decreases GATA6 expression by directly
targeting its 3′-UTR, which in turn inhibits CCA cell in-
vasion and metastasis. We therefore propose that the
restoration of miR-124 expression might represent a po-
tential strategy for CCA therapy.
Additional file
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